Another proof (if needed) that controlling Dz Activity in RA is a very important preventive measure in RA! 179 pts ILD newly developed 9.5% progressed 12.3% no change 74.9% improved 4.5% 5.7% in the LDA group 28.0% non-LDA group (p=0.006) #EULAR2024 POS0408 @AurelieRheumo https://t.co/lKUY32KFiX

Impact of regulatory warning on JAK inhibitors JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death. https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg

Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon? Pregnancy in lupus patients raises concerns due to potential complications like preeclampsia, eclampsia, and increased mortality rates for both mother and baby. https://t.co/Kv6F21UHze https://t.co/ya8lAkSLC2

Might Synovial Biopsy Predict Rheumatoid Treatment Responses? Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. https://t.co/bMUzduZIz9 https://t.co/yFxCvoZukM

Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK

Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. https://t.co/Q7CZoHpDmc https://t.co/cvIRhBJt9Z

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. https://t.co/hYy7Wg2GMJ https://t.co/GVjtf89c3t

Matters of the heart: cardiovascular disease and mortality in RA Patients with RA have up to 2x higher risk of coronary artery disease, plus increased atrial fibrillation and stroke risk. https://t.co/wFs7ds3tF2 https://t.co/GWyXJbeyIn

EULAR 2024 – Day 2 Report (A Difficult RA Day) Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and more. https://t.co/EQ6yC1Sll7 https://t.co/32JHs2KcmW

RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF

Inflammatory bowel disease in spondyloarthritis - does it matter? Do the clinical features of axSpA patients with and without IBD differ? https://t.co/t0wJRXXH0a https://t.co/iZsiP1AgWh